Lyn’s visionary leadership has placed Avalyn at the forefront of respiratory therapeutics, developing groundbreaking inhaled treatments for pulmonary fibrosis. Her strategic prowess, combined with her ...
“I'm really proud of the work we are doing with FEMAP,” said Marner. “London has always been close to my heart, and ...
Among other accomplishments, SeaStar Medical began shipping the SCD Pediatric, brand named QUELIMMUNE ™, for pediatric patients with AKI and sepsis indications in July 2024, having received ...
ARLINGTON, Va., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced that it expects to release financial results for its third quarter and nine-month periods ...
E-Star is developing a platform of Natriuretic Peptides for the treatment of Metabolic Syndrome. The Company's lead asset, MANP, is currently being investigated in a Phase 2 clinical trial. To learn ...
Kineta has completed enrollment in the monotherapy cohorts of the Phase 1 VISTA-101 clinical trial. The ongoing Phase 1 study is now enrolling patients into cohorts evaluating KVA12123 in combination ...
Founded in 2005, the PharmaVoice 100 highlights the driving forces of the life sciences industry who have positively impacted their colleagues, companies and communities. Each honoree is chosen based ...
PharmAla stands ready to support researchers not only with our existing API and 40mg capsules, but in the development of new and novel dosage forms for LaNeo™ MDMA,” said Nicholas Kadysh, CEO, ...
Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system ...
Among PD-L1 IHC, sTILs and 11 immune signatures analyzed, only DetermaIO was significant for interaction, meaning it could predict which patients were most likely to achieve pathologic complete ...
Oragenics Inc. (NYSE American: OGEN), a company focused on developing new treatments for brain-related health conditions, has completed a key study for their new concussion drug, ONP-002. This drug is ...
Host-directed antiviral drugs have the potential to enhance the immune response to viruses from a range of viral families Tonix was awarded a contract with the U.S. Department of Defense for up to $34 ...